New vaccines to control tuberculosis (TB) are urgently needed to fight the global burden of the disease, the increase of resistant strains and the lack of effective vaccines to prevent latent TB infections.
The TNF receptor superfamily member herpesvirus entry mediator (HVEM or TNFRSF14), first identified as a receptor for viral infection, acts as a molecular switch, either activating or inhibiting the immune response depending on the interacting ligand. Previous work found that HVEM binding to B- and T-lymphocyte attenuator (BTLA) initiates an inhibitory signal to effector T cells and that targeting the HVEM-BTLA complex with an antibody reduced tumor growth in a humanized mouse model.
Fudan University has disclosed phosphatidylcholine:ceramide cholinephosphotransferase 2 (SGMS2; SMS2) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, dry eye, pulmonary edema, fatty liver, obesity, type 2 diabetes and Alzheimer’s disease.
Researchers from Fudan University and Southwest University published data from a study that detailed the development of a novel vertebrate model suitable for high-throughput screening of potential antiaging compounds.
One potentially serious complication of obstructive sleep apnea (OSA) is pulmonary hypertension (PH). Based on previous research that revealed involvement of perivascular immune and inflammatory responses in regulation of vascular remodeling and PH processing, researchers from Fudan University investigated the immunologic factors linked to OSA-induced PH.
A recent study by researchers from Fudan University and Tau Cambridge Ltd. explored a novel therapeutic strategy that combines targeting CD47 with ANGPTL3, a key regulator of lipid metabolism, as a potential treatment for atherosclerosis.
Novel vaccines that can effectively target both coronaviruses and influenza viruses would be desirable to counteract the significant health burden these respiratory pathogens pose.
c-Jun N-terminal kinases (JNKs) have been proposed as therapeutic targets in multiple pathologies, including cancer, inflammation and neuronal and metabolic diseases. SP-600125 is one of the first-generation reversible ATP-competitive inhibitors of JNK1/2/3 and has shown anticancer potential against leukemia, lung adenocarcinoma and pancreatic cancer, among others.
More than half of all hearing loss cases are hereditary. Myelin protein zero-like 2, encoded by MPZL2, is widely expressed in cochlear cells in the inner ear. Mutations in MPZL2 have been identified as the second most prevalent cause of mild to moderate hereditary hearing loss.
